Pilot study to analyze COVID-19 vaccination response
Not Applicable
- Conditions
- M05Seropositive rheumatoid arthritis
- Registration Number
- DRKS00024787
- Lead Sponsor
- Medizinische Klinik 3, Universitätsklinikum Erlangen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Complete SARS-CoV-2 vaccination status
- Healthy volunteer or patient with inflammatory disease
Exclusion Criteria
The patient is unwilling or unable to participate in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of SARS-CoV-2 vaccination response in patients with inflammatory diseases and healthy volunteers at time T0 and T1 (3 months) via measurement of antibody levels. Saliva samples and capillary samples are compared with the gold standard venous blood samples.
- Secondary Outcome Measures
Name Time Method - Long-term course of the SARS-CoV-2 antibody titer<br>- Analysis of the impact of demographic and clinical parameters<br>- Acceptance and ease of use of the saliva sample and capillary blood collection